CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

NYU Langone Health

Viraj Lakdawala, System Chief of Emergency Medicine Telehealth

Re-defining Quality of Clinical Care in Telemedicine

Viraj Lakdawala

Viraj Lakdawala

In March 2020, as the COVID-19 pandemic took hold over the metro NYC area, NYU Langone Health saw a 683 percent increase in Virtual Urgent Care (VUC) video visits. Our clinicians saw an average of 20-30 patients per day virtually before the pandemic began, but that rose to over 1,000 per day at the height of COVID-19. Telemedicine’s growth has been incremental and relatively slow over the previous 5-10 years, but the current pandemic has created a need to quickly adapt to a new normal of social distancing and meet the increase in demand for virtual visits.


NYU Langone was well situated to meet this demand due to our existing infrastructure and strong foundation of digital tools, which we quickly scaled up to accommodate a higher capacity of patients. Our Virtual Urgent Care services began with just 40 physicians and has grown to include 289 providers from multiple specialties to treat patients during the pandemic. As telemedicine demand surged, we noticed an increase in not only the volume of patients, but also the type of patient that sought treatment from our providers. Through these services, our clinicians treat a wide range of patients from standard, low acuity patients to those who are acutely ill with multiple comorbidities.


 

Measuring clinical quality has been a standard process for in-person care for many years, but yet, has not been a major component of telemedicine-based care

 


With the significant increase in volumes and higher acuity during the first phase of the COVID pandemic, we noticed that unfortunately, some patients were expiring after VUC visits. Knowing that our patients were suffering untimely deaths, we felt the need to capture data and determine if there were any preventable causes of these deaths. Through a systematic review, we were able to determine risk factors for referrals to the Emergency Departments, as well as identify those patients who may deteriorate to an ICU admission, airway intervention or death.


Measuring clinical quality has been a standard process for in-person care for many years, but yet, has not been a major component of telemedicine-based care. National quality metrics for telemedicine were initially created by the National Quality Forum in 2017 to measure access, financial impact, effectiveness, and patient experience. Unfortunately, these metrics were not built to measure clinical quality of care.


To remedy this, at the beginning of the COVID-19 pandemic, we developed metrics to measure overall quality of care for our Virtual Urgent Care program. The metrics included post-VUC visit ED bounce back rate, death rate within 30 days, and post-VUC ED visit with admission rate, in addition to previously tracked metrics including antibiotic usage rate in upper respiratory infections, and ED referral rates. These metrics were tracked using a dashboard for continuous quality assurance and chart review.


Measuring clinical quality will, of course, need to be specific to the specialty use case, but many metrics can be generalized to multiple specialties. A consensus for clinical quality metrics will need to be developed at a national level in conjunction with the specialty groups. Continuously monitoring quality metrics will help standardize high quality care across the country and allow peers to compare themselves to one other. It will also help drive the conversation towards making reimbursement for telemedicine services a permanent part of healthcare post-pandemic.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://clinical-trial.lifesciencesreview.com/leadership-perspective/redefining-quality-of-clinical-care-in-telemedicine-nwid-1334.html